Trial Profile
Uncontrolled, Open-label, Non-randomized Phase I Study to Investigate Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics of a Single Dose of BAY88-8223 in Japanese Patients With Castration-resistant Prostate Cancer and Bone Metastases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 20 May 2016 Status changed from active, no longer recruiting to completed.
- 19 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 20 Feb 2013 Planned end date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.